Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care
1.5 Credits / Dermatology
View More
Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care
1.5 Credits / Dermatology, Immunology
View More
The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of ...
1.0 Credit / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
An American Journal of Managed CareĀ® Forum: Discussing the Expanding Targeted Therapy Options and Complexities...
1.5 Credits / Breast Cancer, Oncology
View More
Eye on Pharma: Keytruda Biosimilar Deal; German Court Bans Imraldi; New Biosimilars for Japan
June 17th 2025Alvotech and Dr. Reddy's partner to develop a Keytruda biosimilar, a German court bans Humira biosimilar over patent dispute, and Samsung Bioepis enters a strategic agreement with NIPRO Corporation in Japan.
Infliximab Biosimilar Switch Due to Flare Risk: Monitoring Patients Is Crucial for Pharmacists
June 5th 2025Switching from reference infliximab to biosimilars (infliximab-abda and infliximab-dyyb) for rheumatic diseases may lead to treatment delays and a higher risk of disease flares, particularly when the switch is mandated by insurance.
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
British Columbiaās Biosimilar Policy Shows No Impact on Hospital Visits
May 28th 2025Despite a dramatic shift toward biosimilar use following British Columbiaās policy, researchers found no rise in hospital visits or complications, underscoring the real-world reliability of etanercept biosimilars in managing inflammatory arthritis.